drugset / Trial / NCT04840784
First-in Human (FIH) Trial of ETH-155008 in Subjects With B-NHL, CLL/SLL and AML
NaSingle-groupOpen-labelTreatment
Summary
This Trial is a FIH, open-label, multicenter trial to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of ETH-155008 in subjects with R/R B-cell NHL, CLL/SLL and AML who previously received standard treatment or are ineligible for standard treatment options.
Timeline
- Start
- 2021-06-29
- Primary completion
- 2023-05-02
- Completion
- 2023-05-02
Outcome
Outcome not reported
Stopped (Enrollment): “The reasons for early termination is due to slow recruitment”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ETH-155008 | Unknown | 10 mg | Oral |
| Subject | ETH-155008 | Unknown | 20 mg | Oral |
| Subject | ETH-155008 | Unknown | 40 mg | Oral |
| Subject | ETH-155008 | Unknown | 60 mg | Oral |
| Subject | ETH-155008 | Unknown | 80 mg | Oral |
| Subject | ETH-155008 | Unknown | 100 mg | Oral |